Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inotiv Announces Purchase of St. Louis Facility and Plans to Expand Capacity

05/27/2021 | 08:33am EDT

WEST LAFAYETTE, Ind., May 27, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company has completed the purchase of its previously leased St. Louis facility for approximately $4.7 million.  

In early June 2021, the Company intends to commence construction on approximately 20,000 square feet of unfinished shell space at the 50,000 square foot facility, expanding the Company’s capacity to serve its client base with more comprehensive and integrated service offerings. The expansion will include laboratories for increased drug metabolism & pharmacokinetics technology and capability, as well as a new cell and molecular biology suite capable of delivering in vitro solutions in pharmacology and toxicology. The Company will fund the purchase of the facility and expansion costs by proceeds from the public offering that the Company completed in April 2021, and a new $4.8 million term loan from First Internet Bank.

Robert Leasure, Jr., Inotiv’s President and Chief Executive Officer, said, “The purchase and expansion of the St. Louis facility should enable Inotiv to further capitalize on exciting new growth opportunities deriving not only from expanded capabilities in St. Louis, but also from our recent acquisitions of Bolder BioPATH, Inc. and HistoTox Labs, Inc. This strategic expansion is also designed to extend Inotiv’s reach into earlier stages of drug discovery, driving increased engagement of our pharmacology and toxicology operations and histopathology services.”  

About the Company
Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company ContactInvestor Relations
Inotiv, Inc.The Equity Group Inc.
Beth A. Taylor, Chief Financial OfficerKalle Ahl, CFA
(765) 497-8381(212) 836-9614
 Devin Sullivan
 (212) 836-9608

Primary Logo

ę GlobeNewswire 2021
All news about INOTIV, INC.
07/22INOTIV : to Report Third Quarter Fiscal 2021 Financial Results and Host Conferen..
07/21Certain Common Shares of Inotiv, Inc. are subject to a Lock-Up Agreement Endi..
07/21Certain Options of Inotiv, Inc. are subject to a Lock-Up Agreement Ending on ..
07/15SECTOR UPDATE : Health Care Stocks Lower Just Ahead of Closing Bell
07/15SECTOR UPDATE : Health Care Stocks Lacking Much Traction
07/15INOTIV : Buys Laboratories Assets in Tennessee for About $1.3 Million
07/15INOTIV : Acquires Laboratory Instrumentation for Discovery and Development of No..
07/15Inotiv Acquires Laboratory Instrumentation for Discovery and Development of N..
07/15Inotiv, Inc. acquired Physical assets of Novel Therapies for $1.3 million.
07/12INOTIV : Buys MilliporeSigma's Genetic Toxicology Assets
More news
Financials (USD)
Sales 2021 80,2 M - -
Net income 2021 -2,26 M - -
Net Debt 2021 - - -
P/E ratio 2021 -155x
Yield 2021 -
Capitalization 441 M 441 M -
Capi. / Sales 2021 5,50x
Capi. / Sales 2022 3,50x
Nbr of Employees 409
Free-Float 62,3%
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 27,88 $
Average target price 36,00 $
Spread / Average Target 29,1%
EPS Revisions
Managers and Directors
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer, Secretary & VP-Finance
Gregory C. Davis Chairman
John Gregory Beattie Chief Operating Officer
Richard Allen Johnson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INOTIV, INC.0.00%441
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
CELLTRION, INC.-26.60%31 131
SEAGEN INC.-17.54%26 209